Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, The Peter MacCallum Cancer Centre, Melbourne, Australia, describes the high rates of undetectable mesurable residual disease (uMRD) levels in the Phase II CAPTIVATE trial (NCT02910583), which looked at ibrutinib plus venetoclax for first-line therapy in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.